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Bcl-xL inhibition enhances 
Dinaciclib-induced cell death in 
soft-tissue sarcomas
santi Rello-Varona  1, Miriam Fuentes-Guirado1, Roser López-Alemany1, Aida Contreras-
pérez1, Núria Mulet-Margalef1,2, silvia García-Monclús1, oscar M. tirado1,2,3 & Xavier García 
del Muro1,2,4
soft-tissue sarcomas (sts) are an uncommon and heterogeneous group of malignancies that result 
in high mortality. Metastatic STS have very bad prognosis due to the lack of effective treatments. 
Dinaciclib is a model drug for the family of CDK inhibitors. Its main targets are cell cycle regulator CDK1 
and protein synthesis controller CDK9. We present data supporting Dinaciclib ability to inactivate in 
vitro different STS models at nanomolar concentrations. Moreover, the different rhythms of cell death 
induction allow us to further study into the mechanism of action of the drug. Cell death was found to 
respond to the mitochondrial pathway of apoptosis. Anti-apoptotic Bcl-xL was identified as the key 
regulator of this process. Already natural low levels of pro-apoptotic proteins BIM and pUMA in tolerant 
cell lines were insufficient to inhibit Bcl-xL as this anti-apoptotic protein showed a slow decay curve after 
Dinaciclib-induced protein synthesis disruption. Combination of Dinaciclib with BH3-mimetics led to 
quick and massive apoptosis induction in vitro, but in vivo assessment was prevented due to liver toxicity. 
Additionally, Bcl-xL inhibitor A-1331852 also synergized with conventional chemotherapy drugs as 
Gemcitabine. thus, Bcl-xL targeted therapy arises as a major opportunity to the treatment of sts.
Soft-tissue sarcomas (STS) are a group of tumors derived from mesenchymal precursors with scarce incidence 
and rich variability1. Tumors arising from non-epithelial extra-skeletal tissue are generally accounted as STS2. 
There has been much improvement in the understanding of the drivers of STS entities: (i) STSs driven by specific 
chromosome fusions leading to generation of anomalous transcription factors (like FUS-CHOP in myxoid lipo-
sarcoma) or chromatin remodelers (SS18-SSX in synovial sarcoma); (ii) STS that rely on specific mutations (KIT 
in gastrointestinal stromal tumors) and (iii) other STS driven by more complex genomic rearrangements (like 
leiomyosarcomas or some fibrosarcomas)3,4.
STS incidence is difficult to estimate due to their variability, and some reports claim that the usual figures 
could be underestimations1,5. Clinical prognosis and therapeutic outcome is also highly variable in STS2. When it 
is possible, the complete clinical resection make full recovery achievable. However, almost half of the patients will 
develop metastatic disease. Five-year survival rates are still below 50%. So, the weight of STS in total cancer death 
toll is clearly disproportionate to its incidence4,6.
Thus, STS can benefit for new therapeutic approaches6. Among the molecular targeted drugs in development, 
the group of Cyclin-Dependent Kinases (CDKs) inhibitors is one of those concealing major interest7. CDKs con-
stitute a wide family of Ser/Thr protein kinases that require binding with cyclins to act. This coupling enables a 
complex panorama of interactions that keep track on the activation/suppression of specific pathways during cell 
cycle8. Several CDK inhibitors have been identified and tested in vitro as anti-cancer agents7,9. The initial aim of 
CDK inhibitor strategy was the disruption of cell cycle sequence-of-events in order to induce cell death9,10. But it 
was soon understood that CDKs exert more powerful effects over other processes of cell physiology like transcrip-
tion regulation, RNA splicing or protein folding9.
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Dinaciclib is a promising CDK inhibitor, extensively proved pre-clinically11. Its known affinities encompass 
CDK1 (IC50 = 3 nM), CDK2 (IC50 = 1 nM), CDK5 (IC50 = 1 nM) and CDK9 (IC50 = 4 nM)12. Most studies con-
cerning Dinaciclib activity have been focused on the CDK1 control of mitotic entry and CDK9 regulation of gene 
transcription13–15. CDK9-dependent down regulation of anti-apoptotic Bcl-2 family member Mcl-1 is commonly 
regarded as the main mechanism of action of this drug16,17. Some Phase I clinical trials (mostly in pediatric 
leukemia) have also been performed with Dinaciclib. Anti-cancer activity was found to be encouraging, but not 
sufficient for planning monotherapy treatments. Further use of Dinaciclib is thought to rely on combination 
therapies13,18,19.
Combination therapies constitute a hot spot in oncology research. It has become clear its benefits avoid-
ing tumor evolution in favor of drug resistant phenotypes20. Moreover, combination therapies work better than 
monotherapy even in the absence of synergistic behavior21. BH3-mimetics are a new class of anti-cancer drugs 
particularly interesting for these combinations. They are aimed to disturb the balance of the different proteins 
of the Bcl-2 family, thus favoring apoptosis triggering22,23. Alone, BH3-mimetics have been successfully used 
in chronic lymphocytic leukemia since the FDA approval of Venetoclax24. BH3-mimetics work better when the 
cells are already undergoing an apoptotic signaling process that has been compensated by expression or activity 
changes in the Bcl-2 family of proteins. Cells became addicted to these compensatory mechanisms creating then 
an Achilles’ heel for cancer cells23. Recent screenings are showing that BH3-mimetics boost the cytotoxic potential 
of a panoply of chemicals, including CDK9 inhibitors25.
Our aim in the present study is to seek the suitability of Dinaciclib in a series of STS in vitro models as cell 
death inductor, fully characterizing the cellular response to treatment. We have found that Dinaciclib is capable 
of inducing cell death as single agent. The cellular context, particularly the Bcl-2 family balance, at every model is 
decisive for the precise behavior after Dinaciclib incubation. Our data support that Bcl-xL inhibition status is cen-
tral for treatment tolerance. Moreover, Bcl-xL specific inhibitors synergize with Dinaciclib to avoid such tolerance.
Results
Dinaciclib induces cell death in STSs independently of CDK1 and CDK9 expression levels. To 
have a base for inferring the response of STS to Dinaciclib, we analyzed the expression of CDK9, CDK1 and its 
partners Cyclin B1 and A2 in a series of cell lines representative of major groups of STS: synovial sarcoma SW982 
and 1273–99, leiomyosarcoma SK-LMS-1 and SK-UT-1, myxoid liposarcoma 402–91 and 1765–92, dedifferen-
tiated liposarcoma SW872 and myxofibrosarcoma HT-1080 (Fig. 1A). Protein expression was variable among 
the cell lines, from the rather homogenous 43 kDa (lower band) of CDK9 to the more variable CDK1. SW872 
expressed comparatively undetectable levels of CDK1 and its partners. However, the levels of the 55 kDa (upper 
band) of CDK9 were among the highest.
The same set of cell lines was used to test the ability of Dinaciclib to impair cellular viability (read as WST-1 
assay, Fig. 1B). SW982, SW872 and HT-1080 showed fewer decreases in viability at low concentrations, but at 
27 nM differences among the cell lines were reduced. IC50 calculations failed for SW872 and HT-1080 due to high 
disparity of the data (Supplementary Fig. 1A), but actual values should be close to the 12.760 nM obtained for 
SW982.
However, when observed under the microscope, the response to Dinaciclib was more diverse (Fig. 1C). Rather 
than any form of cell death, most cell lines (like the SK-LMS-1 in the image) showed a stop in proliferation with 
almost the same number of cells as seeded. They mostly present a natural control morphology and only few 
detached cells can be observed. Only 402-91 and 1273-99 showed an extensive accumulation of detached, dead 
cells. To clarify this dual effect, we performed an analysis of apoptotic induction by cytofluorometric quantifi-
cation of the levels of the vital stains DiOC6(3) and propidium iodide (DiOC-PI). Comparison among the 8 cell 
lines treated with 25 nM Dinaciclib for 72 h evidenced the two major phenotypes from the microscopical observa-
tions (Fig. 1D). Only 1273-99 and 402-91 presented values of apoptotic cell death exceeding the 50%. Dinaciclib 
concentration of 25 nM was chosen under experimental conditions as the minimal value above which cell death 
reached a plateau as soon as 24 h of treatment either in responsive or in tolerant cell lines (Supplementary Fig. 1B).
In order to confirm that Dinaciclib induced mitochondrial apoptosis, we studied the translocation of 
pro-apoptotic protein Bax to the mitochondria (Fig. 1E) and the arising of 85 kDa band of PARP, a common 
caspase-3 activation reporter (Supplementary Fig. 1C). Both features were confirmed in the sensitive cell lines 
1273-99 and 402-91. Furthermore, the addition of 40 µM pan-caspase inhibitor z-VAD-fmk to the system for 36 h 
was sufficient to abrogate the induction of cell death in both cell lines (Supplementary Fig. 1D,E).
Dinaciclib potential as cell death inducer was conserved also in 3D tissue simulation. 402-91 cells embedded 
in a Matrigel® matrix grew as microspheres. By treating the microspheres with Dinaciclib for 24 h prior staining 
with vital dye H-33342, we clearly observed a reduction of the size of the spheres but also the accumulation of 
bright pyknotic nuclei generated by apoptosis (Fig. 1F).
Taken together, our results show the potential of Dinaciclib as inducer of apoptotic cell death in STS at nano-
molar concentrations.
Dinaciclib effects on cells last after wash-out. To complete our understanding of cellular response to 
Dinaciclib, we performed long-term experiments analyzing cell response after drug wash-out. During the first 
days after Dinaciclib removal, cell lines from the tolerant group (like SW982) underwent cell death albeit the 
identification of a number of viable surviving colonies (Fig. 2A). Cells from the sensitive lines (like 1273-99) 
presented rare, if any, surviving colonies. Additionally, we allowed those colonies to grow into sub-cultures that 
we dubbed Dinaciclib Resistant (DR). Those DR lines were newly challenged with 72 h incubation of Dinaciclib 
25 nM. DRs from the tolerant group did not show any evident difference in behavior from the parental culture. 
But those derived from the sensitive cell lines appeared to have acquired a better fitness against the drug (Fig. 2B). 
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Figure 1. CDK inhibitor Dinaciclib is able to successfully inactivate sarcoma cell lines in a nanomolar range. 
(A) Representative western blot showing expression levels of Dinaciclib targets CDK1 and CDK9, and CDK1 
partners Cyclin B1 and Cyclin A2 among different soft-tissue sarcoma derived cell lines. (B) Viability, measured 
by means of WST-1 reduction test, in a set of different STS cell lines incubated with increasing concentrations 
of Dinaciclib for 72 h; comparing with cells treated only with vehicle. (C) Microscopic imaging showing 
different cell behavior among cell lines when treated with Dinaciclib. (D) Comparison of apoptotic induction, 
cytofluorometric measurement of mitochondrial vital dye DiOC and death marker PI, in different STS 
derived cell lines treated with 25 nM Dinaciclib up to 72 h reveals different sensitivity among the cell lines. (E) 
Immunofluorescent detection of pro-apoptotic protein Bax showing its accumulation in puncta (mitochondria) 
in sensitive cells treated with 25 nM Dinaciclib. (F) 402-91 cells cultured as 3D spheroids by embedding into a 
Matrigel® matrix and treated by Dinaciclib show loss of size and accumulation of pyknotic nuclei as revealed by 
staining with Hoechst-33342 (H-33342).
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Nevertheless, when different experiments were summed up there was no statistical significance in this trend to a 
reduced cell death induction (Fig. 2C).
Therefore, our data suggests that Dinaciclib exerts a long-term effect in cell viability with the added value that 
surviving colonies do not show a strong selection towards drug resistance.
Sensitive and tolerant cell lines differ in cell death protein expression patterns. As the known 
targets of Dinaciclib yielded no clear correlation with drug response, we performed an extensive analysis of pro-
teins involved in cell cycle control among examples of responsive (402-91 and 1273-99) and tolerant (SW982 and 
SK-LMS-1) cell lines (see Fig. 1D). For most proteins (Noxa, BMF, Bax, Bak, Bcl-2, Bcl-xL, Mcl-1, Chk1 or XIAP) 
no significant associations could be made among their expression levels and the tolerance to Dinaciclib (Fig. 3A). 
However, other proteins did show remarkable differences in expression between the two groups.
Tumor suppressor p53 was almost undetectable in Dinaciclib tolerant cells when compared with the respon-
sive ones (Fig. 3A). SK-LMS-1 expressed also relatively low levels of p21Waf1/Cip1 (p21) protein, a p53 target. In this 
regard, it is important to note that SK-LMS-1 cell line has been described as TP53 mutant26. If we compare this 
data with the study of cell cycle changes, we can see that only cell line SW982 presented a statistically significant 
arrest in G2/M phase (Supplementary Fig. 2A). Although most of the Dinaciclib tolerant cell lines did share 
the same trend. To analyze the precise nature of this G2/M blockade we visualized treated and untreated cells 
Figure 2. Dinaciclib did not drive strong selection of resistant clones after drug wash-out. (A) Crystal violet 
staining images showing resistant colonies (arrows) arising from highly sensitive 1273-99 cell line (low 
row) and more tolerant SW982 (upper row) after Dinaciclib wash-out. (B) Microscopic imaging showing 
polyclonal Dinaciclib Resistant (DR) strains response after being newly subjected to 72 h of treatment. (C) 
Cytofluorometric measurement of death induction (subG1 DNA content in PI profiles) for parental and derived 
DR strains from sensitive 1273-99 and 402-91 cell lines after a new cycle of 72 h incubation with Dinaciclib 
25 nM (DINA).
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immunolabelled for Ser10-phosphorylated Histone H3 (p-H3) and p21. Our results confirmed that the arrest was 
not due to accumulation of mitotic events but rather to the arrest of cells in the G2 phase (or in a tetraploid G1), 
as no mitotic figures were observed in 72 h treatment samples (Supplementary Fig. 2B). Besides, in concordance 
with the protein expression data (Fig. 3A), p21 was not induced in SK-LMS-1 cells (Supplementary Figure 2B).
Figure 3. Dinaciclib highly sensitive cell lines present characteristic levels of key regulators of the cell cycle and 
apoptosis triggering. (A) Representative western blots showing protein expression patterns in control duplicates 
from myxoid liposarcoma 402-91, synovial sarcoma 1273-99 and SW982 and leiomyosarcoma SK-LMS-1. 
A representative sample of equal charges marker α-tubulin is also showed. (B) Representative western blots 
showing the decay rhythm of key components of cell cycle and apoptosis regulation at selected end-points of 
Dinaciclib incubation. A representative sample of equal charges marker β-actin is also showed.
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CDK4 inhibitor p16INK4a (p16) presented an expression pattern very similar to p53, being almost absent in 
Dinaciclib-tolerant cell lines. To complete the analysis, we found that senescence-related p16 translocated towards 
the nuclei in tolerant cell lines treated with Dinaciclib, in a way similar to the sensitive ones (whose signal was 
clearly more intense) (Supplementary Fig. 2C). Thus, tolerance to Dinaciclib seems to be linked to the generation 
of a partial G2 arrest without a clear or sustained induction of senescence, as cells finally die in the following days 
(Fig. 2A).
Among the mitochondrial apoptotic control machinery, major differences in protein expression levels were 
found in the small pro-apoptotic BH3-only proteins PUMA and BIM (Fig. 3A). Both were found comparatively 
over-expressed in Dinaciclib sensitive cell lines (402-91 and 1273-99).
The major effect of Dinaciclib via inhibition of CDK9 is the interruption of mRNA transcription16,27. On this 
basis, we analyzed how our main targets evolved upon Dinaciclib incubation (Fig. 3B). As expected, most of the 
proteins showed a radical decrease in expression after Dinaciclib incubation. In concordance with the data from 
Supplementary Fig. 2B, p21 was clearly induced in SW982 cell line. More importantly, anti-apoptotic regulator 
Bcl-xL expression seemed only comparatively slightly reduced by Dinaciclib in all the models but 402-91 cells, 
which showed clear Bcl-xL repression after 48 h of treatment. In contrast, Mcl-1 was early and completely sup-
pressed in all cell lines. Finally, Dinaciclib responsive cell lines retained for longer time the, already higher, levels 
of pro-apoptotic BIM and PUMA.
Summing up, differences in key proteins among STS cell lines can explain particular features of Dinaciclib 
response.
Bcl-xL silencing enhances sensitivity to Dinaciclib in SW982 and SK-LMS-1 cell lines. Based 
on our protein expression data, we developed a hypothetical framework to study the mechanistic of Dinaciclib 
action. Dinaciclib sensitive cells undergo quick apoptosis due to their relative retention of higher levels of 
pro-apoptotic proteins (BIM, PUMA) after quick disappearing of anti-apoptotic Mcl-1 (visible 24 h after treat-
ment, Fig. 3B). Their high levels of p16 (affecting the normal onset of G1 to S transition) prevent surviving cells to 
get arrested in G2 phase (Fig. 4A). On the other hand, Dinaciclib tolerant cells had relatively lower levels of BIM 
and PUMA. And they are lost faster after CDK9 inhibition than in the responsive ones (already undetectable after 
24 h, Fig. 3B). Remaining Bcl-xL is thus fully functional and prevents apoptosis to be triggered and cells proceed 
to G2 when other mechanisms (like p21 induction in SW982) are activated (Fig. 4B). In time, the induced damage 
will force the cells to die (Fig. 2A).
To check the coherence of our hypothesis, we have reviewed the data presented by Booher and co-workers 
in 2014 showing correlation between MCL1:BCL2L1 mRNA ratio and viability after 24 h 100 nM Dinaciclib 
treatment17. By reducing the 250 samples to the ones appertaining to STS, we still found a statistically signifi-
cant correlation, meaning that those cell lines more depending on Mcl-1 were also prone to die after Dinaciclib 
(Supplementary Fig. 3A).
For experimental validation, we addressed the role of Mcl-1 in Dinaciclib-induced cell death by siRNA silenc-
ing (Supplementary Fig. 3B). Although Mcl-1 was successfully depleted, no major increase in cell death was 
observed in SW982 cells (Supplementary Fig. 3C). However, depleting Bcl-xL in Dinaciclib tolerant cell lines 
before Dinaciclib addition (Supplementary Fig. 3D) clearly resulted in an increase of the detachment of cells 
(Fig. 4C). When cell death induction was quantified, the increase of cell death at 24 h of treatment was deemed 
statistically significant (Fig. 4D).
Therefore, our results supported our hypothesis that Bcl-xL is the more relevant counteracting mediator of 
Dinaciclib-induced apoptosis in STS.
BH3-mimetics are able to synergistically enhance and accelerate cell death in STS. To assess 
the possibility of a combination therapy to enhance Dinaciclib action we chose two different BH3-mimetics: one 
with a broad action spectrum, but excluding Mcl-1 (ABT-737) and one specific only for Bcl-xL (A-1331852). 
BH3-mimetics activity over Dinaciclib tolerant cells as monotherapy was negligible (Supplementary Fig. 1A,C) 
but its effect was notable when combined with 25 nM Dinaciclib (Supplementary Fig. 4B,D). Cytofluorometric 
measurement showed that both combinations synergized28 in terms of apoptosis induction after 24 h of treatment 
at very low concentrations (Fig. 5A,B). Moreover, A-1331852 was more efficient than ABT-737. These results 
confirmed our operational hypothesis regarding Dinaciclib mechanism of action.
The next logical step was trying the drug combination in vivo. Previous to performing the in vivo studies, we 
checked in vitro the effects of the combination in immortalised myoblasts C2C12 as an appropriate model for the 
healthy tissue surrounding STSs. C2C12 cells treated with Dinaciclib + A-1331852 for 72 h showed no significant 
increase in cell mortality (Supplementary Fig. 5), indicating that the combination of drug had no deleterious 
effects on healthy cells, thus encouraging us to try the combination in in vivo experiments.
Our first approaches were aimed to assess treatment toxicity and cell growth using Hsd:Athymic NudeFoxn1nu 
mice. We tried different combination regimes of Dinaciclib and ABT-737 based on literature17,29 (Supplementary 
Fig. 6A), unfortunately liver toxicity linked to massive hepatocyte death was observed in all the combinatorial 
cases (Fig. 5C). Moreover, human SK-LMS-1 grew poorly in athymic mice (Supplementary Fig. 6B). In con-
sequence, we moved to a more immunodepressed CB17.Cg-PrkdcscidLystbg-J/Crl mice trying a lower dosage of 
Dinaciclib (due to its high toxicity) and A-1331852 instead of ABT-737 (Supplementary Fig. 6C). SK-LMS-1 
cells grew better in these mice (Supplementary Fig. 6D), but an important percentage of tumors appeared as 
intra-peritoneal masses despite being injected sub-cutaneously (Fig. 5D). Intra-peritoneal tumors grew by sur-
rounding, engulfing and finally invading the kidney (Supplementary Fig. 6E). Those mice were excluded from 
the final experiments. Final in vivo testing of anti-tumoral combined activity of both drugs was unsuccessful in 
terms of mice survival (Fig. 5E). The failure was attributed as a loss of action of the drugs (particularly Dinaciclib) 
due to the dosage reduction we have had to apply to avoid animal suffering. No change in body weight during 
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Figure 4. Bcl-xL is the key regulator of apoptosis triggering after Dinaciclib treatment. (A,B) Schematics of the 
proposed mechanisms of action for the triggering of apoptosis in STS cell lines sensitive (A) and tolerant (B) to 
Dinaciclib. (C) Representative microscopic imaging of SW982 (above) and SK-LMS-1 (below) cell lines treated 
with 25 nM Dinaciclib for 24 h without prior challenge or after 24 h treatment with alternatively a non targeting 
(siNT) or a Bcl-xL directed (siBcl-xL) siRNA. (D) Cytofluorometric quantification of cell death induction 
(measured as subG1 DNA content in PI profiles of fixed cell populations) after sequential treatment with siRNA 
and Dinaciclib. Data are presented as means ± SD. Statistical significance was achieved by the Student’s t test 
from at least three different experiments: *p ≤ 0.05.
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Figure 5. BH3-mimetics targeting Bcl-xL synergize with Dinaciclib to achieve quick apoptosis. (A) 
Cytofluorometric quantification of cell death via DiOC-PI staining of SW982 (left) and SK-LMS-1 (right) 
cell lines treated for 24 h with Dinaciclib 25 nM, ABT-737 80 nM or a combination of both drugs. (B) 
Cytofluorometric quantification of cell death via DiOC-PI staining of SW982 (left) and SK-LMS-1 (right) cell 
lines treated for 24 h with Dinaciclib 25 nM, A-1331852 4 nM or a combination of both drugs. (C) Microscopical 
imaging of H&E stained liver sections from Hsd:Athymic NudeFoxn1nu mice control (left) and treated (right) 
after 3 i.p. injections with 40 mg/Kg Dinaciclib and 7 i.p. injections of ABT-737 who suffered sudden death at 
day 8. (D) Photographs showing typical subcutaneous tumor (left) and atypical intra-peritoneal tumor (right) 
caused by SK-LMS-1 cells in CB17.Cg-PrkdcscidLystbg-J/Crl mice. Percentages of occurrence are presented on 
the images. (E) Kaplan-Meier graph showing the survival of CB17.Cg-PrkdcscidLystbg-J/Crl mice inoculated (s.c.) 
with 5 × 106 SK-LMS-1 cells and afterwards treated with i.p. 20 mg/Kg Dinaciclib, p.o. 25 mg/Kg A-1331852 
or both drugs. Control mice were treated with both drugs vehicles. Time 0 represents the beginning of the 
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the experiment was observed (Supplementary Fig. 6F). Summing up, we could not reach a therapeutic regime in 
which the drugs showed anti-tumor activity without induction of deadly toxicity.
Notwithstanding this set back, we sought to understand whether the key role of Bcl-xL in Dinaciclib-induced 
cell death was a particular feature or part of a more general behavior. Other groups have already shown a positive 
cooperation of BH3-mimetics with CDK inhibitors and anthracyclines25,30. So, we tested another commonly used 
anti-tumor drug in STS therapy: nucleoside analogue Gemcitabine. Our results showed that A-1331852 syner-
gized with Gemcitabine in terms of cell death induction after 48 h of combined treatment (Fig. 5F).
Taking together, these results unveil the specificity of cellular response to CDK inhibitor Dinaciclib and posi-
tively identify Bcl-xL as the key player of apoptosis induction in these systems. More pharmaceutical research will 
be required to achieve a safe way for clinical practice, probably through the development of new delivery methods 
or new molecules with reduced side-effects. Still, this question falls beyond the scope of our study.
Discussion
Dinaciclib is one of the most promising compounds in the group of CDK inhibitors because is able to act by 
meddling in the progression of late steps of the cell cycle, the entry in mitosis, transcriptional regulation and even 
the unfolded protein response14,31,32. It has been studied in clinical trials on cancer entities such as acute leukemia 
and other pediatric malignancies11,13,19. Dinaciclib was well tolerated, but its therapeutic effect as single agent did 
not achieve any total remission. However, in several neoplasias it is considered a good candidate for combination 
therapies7,32,33, including BH3-mimetics25.
Here we present new data on Dinaciclib pre-clinical results in STS cell lines. Our results show that Dinaciclib 
is able, as single agent, to impede cell proliferation in a nanomolar range (Fig. 1B) and to induce cell death at 
least in myxoid liposarcoma 402-91 and synovial sarcoma 1273-99 cells (Fig. 1D). Our model of 3D culture also 
proves that Dinaciclib is able to infiltrate and kill cells in solid tumors (Fig. 1F). These results align with previous 
pre-clinical reports that have also proved the utility of Dinaciclib in different tumor entities15,17,32. Moreover, 
our long-term studies after Dinaciclib removal showed that the deregulation induced by the drug was enough 
to promote a delayed death (five days after drug withdrawal) and that the remnant colonies did not develop an 
enhanced resistance to re-challenge (Fig. 2C). The lack of reinforced tolerance to Dinaciclib in DR lines opens the 
gate to the establishment of repeated administrations or combination procedures34,35.
To do so, a proper cell death mechanism characterization is paramount36. In this sense, our results proved 
that the main mechanism involved in Dinaciclib killing is the mitochondrial apoptotic pathway (Fig. 1D,E and 
Supplementary Fig. 1B–E). Other in vitro studies published with Dinaciclib also pointed to apoptotic mecha-
nisms but they provided a less detailed characterization of the cell death15,16,18. Dinaciclib action involves two 
clearly different processes: cell cycle inhibition and alteration in protein production and homeostasis9,31. The 
study of those cell lines more tolerant to Dinaciclib is helpful as their delayed death allow us to observe other 
variables. Cell cycle profiling showed a trend to an arrest in G2-to-M transition that was only significant in SW982 
(Supplementary Fig. 2A). SW982 cells are also the only cell line able to induce an increase in p21 protein (Fig. 3B 
and Supplementary Fig. 2B). Our data agreed to previous reports in other cancer entities, in which the cell cycle 
arrest was revealed when apoptosis was inhibited by Bax/Bak DKO17. But this mechanism may not be universal 
as most of our Dinaciclib tolerant cell lines did not reach statistically significant mitotic arrest. However, the sen-
sitive cell lines indeed did increase their G2/M and postM (tetraploidy) phases when apoptosis was abrogated by 
z-VAD-fmk (data not shown). So, it appears that the effect on the cell cycle deregulation in our models may be an 
important contributor in the apoptotic triggering. Further research is needed to understand if other proteins (like 
p21) are required for G2 arrest after CDK1 inhibition.
The higher levels of tumor suppressor p53 in Dinaciclib sensitive cell lines (1273-99 and 402-91) is a key fac-
tor underlying Dinaciclib response, as it influences the levels of pro-apoptotic BH3-only proteins among other 
safety signalization processes37. On the other hand, the role of cell cycle regulator p16 is intriguing. It is one of 
the multiple transcripts of the CDKN2A locus, all of them with key functions in the homeostasis of the cell cycle, 
tumor suppression, senescence and aging38–42 The expression of p16 is not directly regulated by p53 but rather by 
Jun-B and Ras via Ets-1/238. However, there are references cross-linking Ets-1/2 transcription factors with Bcl-2 
family expression43–46 and even p53 activity47. In our settings, the sensitive cell lines 1273-99 and 402-91 exhibit 
higher levels of p16 than the tolerant ones (Fig. 3A and Supplementary Fig. 2C). Hence, there is supporting data 
to consider that expression levels of p16 could be linked to an apoptotic-permissive unbalance among the Bcl-2 
family that enhances Dinaciclib sensitivity. As has been proved in other cancer entities, we consider interesting to 
explore the use of p16 as a predictive marker for cell cycle targeted therapies39,42.
Dinaciclib causes a general depletion of protein content in the cell via RNA Polymerase II dephosphorylation 
with different impact depending on protein distinctive half-life7,9,16,17. From our list of proteins of interest, we 
focused in Bcl-xL as its levels decreased in a evident slow rate after Dinaciclib incubation (Fig. 3B). Delayed (48 to 
72 h) depletion of Bcl-xL was seen only in the most sensitive cell line (402-91). In contrast, PUMA and BIM levels 
decreased later in Dinaciclib responsive cell lines (48 h instead 24 h, Fig. 3B). Mitochondrial apoptosis is basically 
regulated by the inhibition status of large anti-apoptotic members of Bcl-2 family of proteins. This inhibition sta-
tus relies on the balance with the pro-apoptotic members of the group, particularly the small BH3-only proteins48. 
treatment. (F) Cytofluorometric quantification of cell death (as subG1 in PI profiles in fixed cells) of SW982 and 
SK-LMS-1 cells treated with 100 nM Gemcitabine (GEM), 4 nM A-1331852 or a combination of both drugs 
for 48 h. Data are presented as means ± SD. Statistical significance was achieved by the Student’s t test from at 
least three different experiments: *p ≤ 0.05; **p ≤ 0.001; ***p ≤ 0.0001. syn. denotes synergistic behavior as 
determined according Valeriote & Lin.
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Published literature has focused in anti-apoptotic regulator Mcl-1 levels as the main mediator of Dinaciclib cyto-
toxicity because its expression drops drastically after treatment16–18. Recently, a more comprehensive study from 
Inoue-Yamauchi and co-workers lead to a more complex panorama in which every member of the Bcl-2 fam-
ily has a role in the apoptotic triggering25. For STS, the limited cohort from Booher and co-workers provides 
correlation between Dinaciclib sensitivity and Mcl-1/Bcl-xL ratio (Supplementary Fig. 3A). However, our data 
showed that Mcl-1 levels are already low in SW982 cells (Fig. 3A) and quickly become almost undetectable upon 
Dinaciclib treatment in all cell lines (Fig. 3B). So, we envisaged a mechanistic hypothesis that put remnant Bcl-xL 
interaction with BIM and/or PUMA in the decision point of apoptosis triggering in STS cell lines (Fig. 4A-B). 
When Dinaciclib is added, its effect over CDK9 causes a quick depletion in anti-apoptotic protein Mcl-1 but the 
effect over BIM or PUMA is weaker (and negligible on p53). PUMA and BIM are thus capable to initiate mito-
chondrial apoptosis by inhibition of Bcl-xL. Yet SW982 and SK-LMS-1 have low levels of BIM and PUMA. In the 
presence of Dinaciclib, the remaining levels of Bcl-xL are enough to sustain cell viability for longer time. Then, 
the effects over the cell cycle (via CDK1) become detectable as a trend (significant in SW982) to a G2 blockade. 
Silencing experiments with siRNA confirmed our suspicion, as Bcl-xL induced a clear increase in detached cells 
whereas Mcl-1 inhibition exerted no major difference (Fig. 4C,D and Supplementary Fig. 3B,C).
Bcl-xL involvement as key mediator of apoptosis triggering has been previously described in several contexts 
including cell cycle alterations and other sarcoma entities49–51. Among the different Bcl-2 family interactions, 
Bcl-xL has strong affinity for pro-apoptotic BH3-only proteins PUMA and BIM49,50,52,53. BH3-mimetics are a new 
class of drugs precisely designed to benefit of this interaction to promote cell death23. Since the recent FDA 
approval of Venetoclax, these molecules are in the spotlight of cancer research, albeit some groups are calling 
to improve the accurateness of data analysis54. A more detailed research in their precise mechanism of action is 
needed in order to design meaningful combinations for treatment. Nevertheless, we decided to go ahead and test 
our working hypothesis by designing drug combination testing in vitro. Two BH3-mimetics were chosen: ABT-
737, a rather generic compound that, inhibits Bcl-2, Bcl-w and Bcl-xL proteins55 and A-1331852, a newer and 
Bcl-xL specific molecule56. Neither of them induced a relevant cell death accumulation as monotherapy, but when 
combined with Dinaciclib they showed a fast synergistic induction of cell death in both SW982 and SK-LMS-1 
cells (Fig. 5A,B and Supplementary Fig. 4). The effects were clearly better with A-1331852 than with ABT-737, 
providing more support to our mechanistic hypothesis. Regretfully, we encountered too many problems at esca-
lating our settings to in vivo experimentation (Fig. 5C–E and Supplementary Fig. 6). The main issue was the 
development of deadly liver toxicity, that was already glimpsed in literature57. Our data supports the need of more 
pharmaceutical research in order to generate a safer treatment protocol.
In the past few years, other groups have recognized the potential of BH3-mimetics in combination approaches 
to kill cancer cells. As previously commented, Inoue-Yamauchi and co-workers, using screening technologies in 
a small-cell lung cancer model, found that anti-tumor properties of CDK9 inhibitors and anthracyclines were 
boosted when combined with those molecules25. Research in STS has also pointed to the suitability of such com-
binations. Possible combinations for BH3-mimetics include anthracyclines, histone deacetylase inhibitors, tubu-
lin poisons and etoposide30,58–60. Here, we add to the list Dinaciclib and Gemcitabine (Fig. 5F) and we point that 
the major focus should be put in Bcl-xL inhibitors. Both, our data and the previous literature support the conclu-
sion that Bcl-xL targeted molecules behave better than generic BH3-mimetics. The existence of a single molec-
ular route to explain this multiple activity seems unlikely. Bcl-xL has been identified as a key player of cell death 
triggering after mitotic arrest50. This can explain the synergy reported with tubulin poisons or other compounds 
that induced strong mitotic arrest. But, it is not the case with Dinaciclib, as we obtained no relevant mitotic arrest 
linked to the cell death triggering. The G2 blockage reported for SW982 occurs at 72 h and combined cell death 
is verified at 24 h. Thus, in our setting it is more relevant the quick loss of protein players once Dinaciclib has dis-
turbed the process of protein synthesis. The higher life time of Bcl-xL positions it as the cornerstone of apoptotic 
induction. For Gemcitabine we cannot discard that the mechanism proceeds more similarly to the observed for 
mitotic disruptors. In this case, combined action takes more time to be verified (48 h vs. 24 h with Dinaciclib) 
showing that BH3-mimetics did not exert a pro-apoptotic activity by themselves. Indeed, their function is simply 
to push towards cell death after another injury has been detected in the cell.
Taking together, we have extensively showed that Dinaciclib (or an improved CDK9 inhibitor) is a suitable 
candidate for clinical trials in STS. It is capable to effectively kill STS cell lines in a relevant fashion, without 
inducing a strong selection towards drug resistance. Moreover, when combined with BH3-mimetics its action 
gets boosted in a remarkable way. Pharmacological research is, however, required in order to address the elevated 
toxicity linked to this drug.
Methods
Cell culture. Cell lines (Table 1) were cultured in RPMI-1640, except for C2C12 which were grown in DMEM. 
Media were supplemented with 10% (v/v) heat-inactivated FBS, 1% (v/v) Penicillin-Streptomycin and 1% (v/v) 
HEPES (Gibco). All cell lines were incubated in an AutoFlow NU-4750 Incubator (NuAire) at 37 °C in a humidi-
fied atmosphere of 5% CO2 in air. Otherwise specified, plasticware were purchased from Jet BioFil.
Authenticity of the cell lines was routinely confirmed by STR profiling analysis done at qGenomics SL 
(Esplugues de Llobregat, Barcelona, Spain).
Exponential growing cells were used for all experiments. Depending on cell size and proliferation rates, 
80,000–180,000 cells were seeded in 12-well plates (or 1–2 million cells in P100 dishes) and allowed to grow for 
24 h prior to treatment. Cells were routinely observed and photographed by means of an IX70 inverted epifluo-
rescence microscope (Olympus).
For 3D cultures, we seeded 80,000 cells mixed in 1:1 dilution of medium and Matrigel® (Corning Inc.) in 
24-well plates already coated with a solidified layer of pure Matrigel®. Cells were kept in these conditions for 72 h 
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to allow microsphere formation prior to treatment. Cell-permeable DNA-binding dye Hoechst-33342 (Molecular 
Probes) was added (10 μg/mL final concentration in medium) for nuclei visualization.
Chemicals and treatments. Dinaciclib (CAS 779353-01-4) was purchased from Selleckchem and diluted in 
DMSO (Sigma-Aldrich) to a 100 μM concentration. Used dilutions were made in complete medium. Pan-caspase 
inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone (z-VAD-fmk, CAS 187389-52-2) was 
purchased from ApexBio and diluted in DMSO to form a 50 mM stock solution. Used dilutions (40 μM) were 
made in complete medium. Generic BH3-mimetic ABT-737 (CAS 852808-04-9) was obtained from ApexBio and 
diluted in DMSO to an initial 10 mM stock. The Bcl-xL specific inhibitor A-1331852 (CAS 1430844-80-6) was 
purchased from ChemieTek and a 3 mM initial stock solution in DMSO was employed. The nucleoside analog 
Gemcitabine (CAS 122111-03-9) was obtained as hydrochloride salt from LC Laboratories and diluted in DMSO 
to form a 1 mM stock. In every case, further dilutions were made taking into account not to surpass 0.1% (v/v) 
content of DMSO in media.
proliferation and long-term clonogenic assay. For proliferation assessment, 3,000–5,000 cells were 
seeded in 96-well plates and treated with increasing concentrations of Dinaciclib, ABT737, A-1331852 or com-
binations of drugs for variable times up to 72 h. At desired time points, cells were incubated with WST-1 reagent 
(Roche) diluted 1:10 in complete medium up to 2 h in the incubator. Soluble formazan salt production from 
WST-1 was measured by absorbance (λ = 440 nm) in a PowerWaveXS plate reader spectrophotometer (BioTek 
Instruments). IC50 values were calculated using Prism software (GraphPad).
Long-term analyses of post-treatment survival were performed by seeding 180,000–300,000 cells in 6-well 
plates. Cells were cultivated with 25 nM Dinaciclib for 72 h prior drug wash-out and kept in culture up to a week. 
At that point cells were transferred to new plates to recover Dinaciclib Resistant strains or were stained with 0.5% 
(w/v) Crystal Violet (Sigma-Aldrich) solution in 1:5 Methanol:PBS for 20 min and washed with water. Images 
reflect representative results of at least three independent experiments.
siRNA experiments. Cells were transfected using DharmaFECT (Dharmacom, GE HealthCare) following 
manufacturer’s instructions. ON-TARGETplus Non-Targeting Control Pool (Dharmacom) was used as reference 
and customized siRNA sequences were purchased from Sigma-Aldrich: 5′-AAUAACACCAGUACGGACGGG-3′ 
for Mcl-1 and 5′-ACAAGGAGAUGCAGGUAUUUU-3′ for Bcl-xL.
Flow cytometry. For the simultaneous quantification of plasma membrane integrity and mitochondrial 
transmembrane potential (Δψm), living cells were collected and stained with 1 μg/mL propidium iodide (PI, 
Molecular Probes) and 40 nM of DiOC6(3) (DiOC, Sigma-Aldrich) for 30 min at 37 °C. DiOC is a cyanine deriv-
ative that accumulates in functional mitochondria and dissipates when Δψm is lost. PI is a cell impermeable 
cationic stain (DNA intercalating) that accumulates in cell nuclei once the plasma membrane is no longer a 
barrier. So, we can identify cells committed to apoptosis (low levels of DiOC but still excluding PI), cells that 
suffered sudden necrosis (positive to PI but still retaining DiOC labeling) and cells that progress from apoptosis 
to secondary necrosis (negative to DiOC and positive to PI). Live cells (positive to DiOC and negative to PI) were 
not represented.
For cell cycle analysis, cells were fixed in 70% ice-cold ethanol and labeled with 50 µg/mL PI in PBS con-
taining 500 µg/mL RNase (Sigma-Aldrich). This approach also allows cell death quantification as subG1 events. 
Cytofluorometric determinations were performed employing a Gallios flow cytometer and data were statistically 
evaluated using Kaluza software (Beckman Coulter). Only the events characterized by normal forward scatter 
(FSC) and side scatter (SSC) parameters were included in sub-sequent analyses.
Western blot analysis. Cells were lysed with RIPA Buffer (ThermoFisher Scientific) containing Protease 
Inhibitor Cocktail Tablets and Phospatase Inhibitor Cocktail Tablets (Roche). Lysates were sonicated and centri-
fuged at 13,000 rpm for 20 min (at 4 °C). Protein content was determined with BCA assay (Pierce Biotech.). Lysate 
aliquots (50 μg) were resolved by 8–12% SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad 
Cell line Origin Provider
SW982 Synovial Sarcoma ATCC
1273-99 Synovial Sarcoma Dr. Carmen de Torres, Hospital Sant Joan de Deu (Esplugues de Llobregat, Spain)
SK-LMS-1 Leiomyosarcoma ATCC
SK-UT-1 Leiomyosarcoma CLS
402-91 Myxoid Liposarcoma Prof. Roberto Mantovani (Università degli Studi di Milano, Milan, Italy)
1765-92 Myxoid Liposarcoma Prof. Roberto Mantovani
SW872 Dedifferentiated Liposarcoma ATCC
HT-1080 Fibrosarcoma ATCC
C2C12 Immortalised Mouse Myoblasts ATCC
Table 1. List of cell lines employed in the study.
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Laboratories). After blocking with 5% skimmed milk in PBS containing 0.2% (v/v) Tween-20 (Sigma-Aldrich) for 
1 h (RT), membranes were incubated overnight at 4 °C with the appropriate primary antibody dilution (Table 2).
Blots were then incubated at room temperature (RT) for 1 h with Goat anti-Rabbit/anti-Mouse IgG (H + L) 
horseradish peroxidase–conjugated secondary antibodies (#31460 and #31430, Thermo-Fisher Scientific) and 
bands were revealed in Hyperfilm ECL (Amersham) by enhanced chemiluminescence employing ECL Western 
Blotting Substrate (Pierce Biotech.). Immunodetection of β-actin (#ab49900) or α-tubulin (#ab28439, both from 
Abcam) were used as loading reference.
Immunofluorescence. Cells (30,000–80,000) were seeded over glass coverslips placed into 24-well plates 
prior to treatment. At desired end-points, cells were fixed by 30 min incubation in 4% (w/v) paraformaldehyde 
(Sigma-Aldrich) in PBS. Cells were sequentially permeabilized with 0.1% (w/v) SDS in PBS (USB Corp.) and sub-
jected to antigen blocking with 10% (v/v) FBS in PBS (both for 20 min). Primary antibodies employed were Bax, 
p21Waf1/Cip1, p16INK4a and phospho(Ser10)-Histone H3 (Table 2). Secondary antibodies were Goat anti-Mouse or 
anti-Rabbit IgG (H + L) Secondary Antibodies, conjugated either with Alexa Fluor® 488 or 594 (ThermoFisher 
Scientific: #A-11001, #A-11005, #A-11008 and #A-11012). DNA counterstaining was performed upon 10 min 
incubation with 5 μg/mL solution of DAPI (Molecular Probes). Photographs were taken with either an Axio 
Observer.Z1 (Carl Zeiss AG) or a DM6000B (Leica Microsystems) epifluorescence microscope. Images were ana-
lyzed with Image J software (freely available from the National Institutes of Health at the address https://imagej.
nih.gov/ij/).
In vivo experimentation. For animal experimentation, Dinaciclib was purchased to ApexBio as powder 
and formulated in 20% hydroxypropyl beta-cyclodextrin (HPβCD, Sigma-Aldrich) in de-ionized water. The for-
mulation was stored at 5 °C, used within 7 days and warmed to RT and vortexed for 3 sec before intraperitoneal 
(i.p.) administration. ABT737 was also obtained from ApexBio and formulated in 30% propylene glycol, 5% 
Tween 80, 10% DMSO, 3.3% dextrose (all from Sigma-Aldrich) in water. Aliquots were kept at RT and vor-
texed before i.p. administration. A-1331852 was provided by Abbvie under Material Transfer Agreement and 
formulated in 60% Phosal 50 PG (standardized phosphatidylcholine, PC, concentrate with at least 50% PC and 
propylene glycol; gently provided by AbbVie), 27.5% poly-ethylene glycol (PEG) 400, 10% ethanol, and 2.5% 
DMSO (all from Sigma-Aldrich). First, A-1331852 powder was suspended in DMSO and ethanol until a uniform 
cloudy suspension was obtained. PEG 400 and Phosal were then added and the solution was mixed by vortexing. 
The solution was allowed to sit for approximately 30 min after adding all the excipients helped to achieve a clear 
solution. A sonicator was also used for less than 10 min. Formulated compound was stored in an amber bottle at 
room temperature to protect it from light. A-1331852 formulation was administered per os (p.o.) by using an oral 
gavage. Dosages and administration regimes tested are summarized in Supplementary Fig. 6A–C.
Female Athymic (Hsd:Athymic NudeFoxn1nu) mice (n = 20) were purchased at Envigo. Female SCID® Beige 
(CB17.Cg-PrkdcscidLystbg-J/Crl) mice (n = 40) were acquired at Charles River. Animal care procedures were fol-
lowed according to the Institutional Guidelines for the Care and Use of Laboratory Animals. Ethics approval 
was provided by the institutionally appointed “IDIBELL Ethics Committee for Animal Experimentation”. 
IDIBELL animal facility abides to the Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) regulations.
Target Provider Catalog number Dilution
Noxa Calbiochem OP180 1:500
p16INK4a (CDKN2A) Abcam ab108349 1:1000
Bax Cell Signaling Technology 5023 1:2000
p21Waf1/Cip1 Cell Signaling Technology 2947 1:1000
PUMA Cell Signaling Technology 12450 1:1000
Bmf Abcam ab181148 1:2000
Bak Cell Signaling Technology 12105 1:2000
Bcl-2 Cell Signaling Technology 4223 1:1000
Bcl-xL Cell Signaling Technology 2764 1:2000
CDK1 (cdc2) Cell Signaling Technology 9116 1:1000
Mcl-1 Cell Signaling Technology 4572 1:1000
Cyclin A2 Cell Signaling Technology 4656 1:1000
Chk1 Cell Signaling Technology 2360 1:1000
XIAP BD Transduction Laboratories 610762 1:5000
Cyclin B1 Cell Signaling Technology 4138 1:1000
BIM Cell Signaling Technology 2933 1:1000
CDK9 Cell Signaling Technology 2316 1:1000
PARP Cell Signaling Technology 9542 1:1000
phospho(Ser10)-Histone H3 Cell Signaling Technology 9706 1:1000
Table 2. List of primary antibodies employed for western blotting and/or immunofluorescence.
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Five million (5 × 106) SK-LMS-1 cells in 1:1 RPMI:Matrigel® were subcutaneously (s.c.) injected in the right 
dorsal flank of the mice. Tumor growth was followed by a caliper and volume was extrapolated using the formula 
vol = (L × l2)/2 were “L” refers to the major and “l” to the minor diameter measured. Drug treatments started 
when tumors reached a volume of approximately 100 mm3. Mice were blindly randomized into the different 
groups by using a 6-faced dice.
After the end of the experiment, tumors and organs of interest were extracted and fixed in 3.7% Formol 
solution in PBS (Sigma-Aldrich) for 24 h. Afterwards, samples were paraffin embedded and prepared for 
Hematoxylin-Eosin (H&E) staining following standard protocols. Microscopical imaging was performed by 
means of a Nikon Eclipse 80i workstation. Photographs were analyzed using GNU Image Manipulation Program 
(GIMP) software (freely available at http://www.gimp.org).
statistical Analysis. Unless otherwise stated, experiments were performed thrice. Data were analyzed for 
statistical significance using Student’s t test, using either Calc (The Document Foundation) or Excel (Microsoft 
Corporation) software; p ≤ 0.05 was regarded as significant. Synergistic behavior of drugs in combination was 
assessed by means of the comparison of the surviving fractions according to the method of Valeriote & Lin. Mice 
survival curves were analyzed using Prism (GraphPad Software Inc.).
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